top of page

Asian licensing deals for Ergomed and Aeterna Zentaris’ endometrial cancer drug

The UK drug development company, Ergomed‘s co-development partner, Aeterna Zentaris has achieved two further licensing deals for zoptrex.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page